Advertisement

Contribution of Estrogen Receptors to the Strategy of Breast Cancer Treatment

  • J. C. Heuson
  • R. Paridaens
  • E. Ferrazzi
  • N. Legros
  • G. Leclercq
  • R. J. Sylvester

Abstract

Polychemotherapy and hormonal therapy are currently the major therapeutic modalities in advanced breast cancer. The former is the most effective (≥ 50 percent response rate) but the second is less toxic, with a response rate of about 30%. The recent development of estrogen receptor determination in breast cancer tissue samples has improved the clinician’s ability to use these modalities either separately or together in an optimum manner.

Keywords

Breast Cancer Estrogen Receptor Endocrine Treatment Advanced Breast Cancer Breast Cancer Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. AMA Council on drugs, 1960, Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study on nine-hundred forty-four patients. JAMA, 172, 1271.CrossRefGoogle Scholar
  2. Brambilla, C., De Lena, M., Rossi, A., Valagussa, A., and Bonadonna, G., 1976, Response and survival in advanced breast cancer after two non crossresistant combinations. Br. Med. J., 1, 801–804.PubMedCrossRefGoogle Scholar
  3. Brambilla, D., Valagussa, A., and Bonadonna, G., 1978, Sequential combination chemotherapy in advanced breast cancer. Cancer Chemother. Pharmacol., 1, 35.PubMedCrossRefGoogle Scholar
  4. Case, D.C., Young, C.W., Nisce, L., Lee, B.J. III, and Clarckson, B.D., 1976, Eight-drug combination chemotherapy (MOPP and ABVD) and local radiotherapy for advanced Hodgkin’s disease. Cancer Treatment Reports, 60, 1217–1223.PubMedGoogle Scholar
  5. Cohen, M.H., Ihde, C.C., Bunn, P.A., Fossieck, B.E., Matthews, M.J., Shackney, S.E., Johnston-Early, A., Makuch, R., and Minna, J.D., 1979, Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treatment Reports, 63, 163–175.PubMedGoogle Scholar
  6. Cox, D.R., 1970, The analysis of binary data. Methuen and Co Ltd., London.Google Scholar
  7. E.O.R.T.C. Breast Cancer Cooperative Group, 1973, Standards for the assessment of estrogen receptors in human breast cancer. Europ. J. Cancer, 9, 379–381.CrossRefGoogle Scholar
  8. Goldenberg, I.S., 1964, Testosterone Propionate therapy in breast cancer. JAMA, 188, 1069.PubMedCrossRefGoogle Scholar
  9. Hayward, J.L., Carbone, P.P., Heuson, J.C., Kumaoka, S., Segaloff, A., and Rubens, R.D., 1977, Assessment of response to therapy in advanced breast cancer. Europ. J. Cancer, 13, 89–94.CrossRefGoogle Scholar
  10. Heuson, J.C., Engelsman, E., Blonk-van der Wijst, J., Maass, H., Drochmans, A., Michel, J., Nowakowski, H., and Gorins, A., 1975, Comparative trial of Nafoxidine and ethinyloestradiol in advanced breast cancer. An E.O.R.T.C. Breast Cancer Cooperative Group Study. Br. Med. J., 2, 711–713.Google Scholar
  11. Heuson, J.C., Longeval, E., Mattheiem, W.H., Deboel, M.C., Sylvester, R.J., and Leclercq, G., 1977, Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer, 39, 1971–1977.PubMedCrossRefGoogle Scholar
  12. Heuson, J.C., Sylvester, R., and Engelsman, E., 1980, Alternating cyclical hormonal cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An E.O.R.T.C. Trial. Europ. J. Cancer, in press.Google Scholar
  13. Jensen, E.V., Block, G.E., Smith, S., Kyser, K., and de Sombre, E.R., 1971, Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr., 34, 55–70.PubMedGoogle Scholar
  14. Leclercq, G., Heuson, J.C., Schoenfeld, R., Mattheiem, W.H., and Tagnon, H.J., 1973, Estrogen receptors in human breast cancer. Europ. J. Cancer, 9, 665–673.CrossRefGoogle Scholar
  15. Leclercq, G., Heuson, J.C., Deboel, M.C., and Mattheiem, W.H., 1975, Oestrogen receptors in breast cancer: a changing concept. Br. Med. J., 1, 185–189.PubMedCrossRefGoogle Scholar
  16. Leclercq, G., and Heuson, J.C., 1976, Estrogen receptors in the spectrum of breast cancer. Current problems in Cancer, 1, n° 6, R.C. Hickey ed., Year Book Medical Publishers, Inc. Chicago, pp. 1–34.Google Scholar
  17. McGuire, W.L., Carbone, P.P., Sears, M.E., and Escher, G.C., 1975, Estrogen receptors in human breast cancer: an overview, in: Estrogen receptors in human breast cancer. McGuire W.L., Carbone P.P. and Vollmer E.P., eds., Raven Press, New York, pp. 1–7.Google Scholar
  18. Mouridsen, H.T., and Palshof, T., 1980, CMF versus CMF plus Tamoxifen in advanced breast cancer in postmenopausal subjects. Europ. J. Cancer, in press.Google Scholar
  19. Silverstein, M.J., Byron, R.L. Jr., Yonemoto, R.M., Riihimaki, D.U., and Schuster, G., 1975, Bilateral adrenalectomy for advanced breast cancer: a 21 year experience. Surgery, 77, 825–832.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • J. C. Heuson
    • 1
  • R. Paridaens
    • 1
  • E. Ferrazzi
    • 1
  • N. Legros
    • 1
  • G. Leclercq
    • 1
  • R. J. Sylvester
    • 1
  1. 1.Institut J. BordetCentre des tumeurs de l’université libre de BruxellesBruxellesBelgium

Personalised recommendations